Henry Schein, US8064071025

Henry Schein stock trades before November 3 earnings

Published on 10/07/2026 at 07:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 6.70 percent to USD 3.5 billion year over year. Henry Schein stock costs EUR 75.25 on October 7, 2026 versus EUR 75.00.

Isometrische 3D-Illustration der Lieferkette von Medizinprodukten von Produktion zu Klinik
Henry Schein US42548G1040 Wertschöpfungskette vom Hersteller über Lager bis zur Zahnarztpraxis isometrisch dargestellt, Illustration mit AI erstellt.

Henry Schein (ISIN US8064071025) was trading at EUR 75.25 at Lang & Schwarz on October 7, 2026 at 7:44 a.m. CEST, plus 0.33 percent versus the prior close of EUR 75.00. Trefis lists November 3, 2026 as the company's next earnings release.

Quarterly growth carries the story

According to The Globe and Mail, Henry Schein reported USD 3.5 billion of sales in the second quarter of 2026, up 6.70 percent from the second quarter of 2025. The same transcript records GAAP net income of USD 94 million, or USD 0.82 per diluted share, versus USD 86 million and USD 0.70 in the prior-year quarter.

The comparison favors earnings more than revenue: non-GAAP diluted earnings per share increased 15.50 percent to USD 1.27, while adjusted EBITDA rose 12.70 percent to USD 288 million, according to The Globe and Mail.

Guidance leaves a higher bar

Management raised full-year 2026 sales-growth guidance to 4.50 percent-5.50 percent from 3.00 percent-5.00 percent. Non-GAAP diluted EPS guidance moved to USD 5.29-5.39 from USD 5.23-5.37, as reported in the August 4, 2026 call carried by The Globe and Mail.

The key execution measure is the value-creation program. Henry Schein is targeting more than USD 200 million of operating-income improvement over several years and a USD 125 million run rate by the end of 2026, but the guidance excludes further remeasurement gains and does not provide GAAP guidance.

Technology adds a second operating lever. Henry Schein One had nearly 13,000 subscribers across Dentrix Ascend and Dentally in the second quarter, and recurring revenue represented 90 percent of the unit's revenue, according to The Globe and Mail. That mix gives the business a recurring counterweight to lower-margin distribution sales.

Stock sits in pre-market

Henry Schein's euro quote was EUR 75.25 at Lang & Schwarz at 7:44 a.m. CEST on October 7, 2026, in the pre-market phase for the Xetra perspective. The price was EUR 0.25 above the Lang & Schwarz prior close of EUR 75.00, equal to plus 0.33 percent.

Trefis lists a market capitalization of USD 9.6 billion on October 5, 2026, while the finance quote shows USD 61.95 to USD 92.18 as the 52-week range as of October 6, 2026. The upcoming November 3 earnings date gives the next scheduled checkpoint for whether the higher 2026 guidance is translating into sustained earnings growth. The further course of trading is shown by the continuously updated real-time quote of Henry Schein stock.

Henry Schein stock facts

  • Company: Henry Schein, Inc.
  • ISIN: US8064071025
  • Ticker: HSIC
  • Primary exchange: Nasdaq
  • Price Lang & Schwarz as of October 7, 2026, 7:44 a.m. CEST: EUR 75.25
  • Change versus prior close: plus 0.33 percent
  • Prior close Lang & Schwarz October 6, 2026: EUR 75.00
  • Market capitalization: USD 9.7 billion as of October 6, 2026
  • 52-week range: USD 61.95-92.18 as of October 6, 2026
  • Sector / Industry: Healthcare / Medical - Distribution
  • Next earnings date: November 3, 2026

More news and analyses on Henry Schein stock

Disclaimer...

en | US8064071025 | HENRY SCHEIN | boerse | 70251321 | bgmi